27Nov 2021
Risk of Osteonecrosis of the Jaw under Denosumab Compared to Bisphosphonates in Patients with Osteoporosis

Risk of Osteonecrosis of the Jaw under Denosumab Compared to Bisphosphonates in Patients with Osteoporosis

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with antiresorptive treatment. There is little evidence regarding the incidence of ONJ among patients with osteoporosis who are treated with denosumab versus bisphosphonates (BPs). The aim of this study was to determine the risk of ONJ in a real‐world population. Subjects who underwent at least one dual‐energy X‐ray absorptiometry (DXA) examination were included in the osteoporosis register of the Swiss Society of Rheumatology between January 1, 2015, and September 30, 2019. Statistical analyses included incidence rates, rate ratios and hazard ratios for ONJ, considering sequential therapies and drug holidays as covariates. Among 9’956 registered patients, 3’068 (89% female, median age 69 years [63 to 76]) were treated with BPs or denosumab for a cumulative duration of 11’101 and 4’236 patient‐years, respectively...

  • #orthopaedics

Like

Save

Share